source
- Biogen advances tau-targeting Alzheimer drug to Phase 3 despite mixed Phase 2 dataBiogen reported results from a Phase 2 trial of its tau-targeting Alzheimer’s candidate diranersen (BIIB080). The study measured tau levels in cerebrospinal fluid and brain tissue of patients with…
- AVB-001 Cell Therapy Demonstrates Safety and Immune Activation in Platinum-Resistant Ovarian CancerAVB-001, an encapsulated interleukin-2 cell therapy, was evaluated in patients with platinum-resistant high-grade serous ovarian carcinoma. The study reported that the treatment was well tolerated.…